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The antibiotic, tautomycin, was found to be a potent inhibitor of protein phosphatases and equally effective for the type-l and type5A enzymes. 
For the catalytic subunits of the type-l and type-2A phosphatases the IC,, value was 22 to 32 nM. For the phosphatase activity present in chicken 
gizzard actomyosin the IC,, value was 6 nM. Tautomycin had no effect on myosin light chain kinase activity. Tautomycia induced a Ca2+-indepen- 
dent contraction of intact and permeabilized smooth muscle fibers and this was accompanied by an increase in the level of myosin phosphorylation. 
Thus, tautomycin by virtue of its ability to inhibit phosphatase activity is a valuable addition for studying the role of protein phosphorylation. 
Tautomycin; Protein phosphatase inhibitor; Smooth muscle contraction 
1. INTRODUCTION 
Tautomycin is an antibiotic isolated from Wep- 
tonlyces spiroverticillatus [l-.3] that was found to in- 
hibit the endogenous protein phosphatases of mouse 
brain [4]. Our objectives in the experiments described 
here were to examine the effects of tautomycin on 
defined protein phosphatases, specifically type-l and 
type-2A and also to evaluate its action on the contrac- 
tion of smooth muscle fibers. It was found that 
tautomycin is a potent inhibitor of type-l and type-2A 
phosphatases and induces contraction of smooth 
muscle under Ca *‘-free conditions. Thus, tautomycin is 
similar in its actions to calyculin-A and to a lesser extent 
okadaic acid [5] and is an additional and valuable tool 
for evaluating roles of protein phosphorylation in 
various systems. 
30°C using the “P-labeled 20 kDa myosin light chain (MLC) ob- 
tained from turkey gizzard [G]. Phosphatase activity was calculated 
from initial linear rates [5]. Activity of chicken gizzard endogenous 
phosphatase was determined from the rate of dephosphorylation of 
phosphorylated MLC on removal of Ca” and ATP (71. 
2.2. Cytosolic Cd’ level and muscle tensiori 
Cytosolic Ca2+ level ([Ca’+]i) was measured simultaneously with 
muscle contraction as reported previously 181. Strips of rat aorta 
(5-10 mg wet weight) were loaded with 5 pM acetoxy methyl ester of 
fura- for 3 h at 23-25°C and then placed in a tissue bath at 37°C. 
Each muscle strip was illuminated alternatively (48 Hz) with 340 and 
380 nm light, and emission was detected at 500 urn. The ratio of the 
500 nm fluorescence induced by 340 ZG; and 380 nm excitation was 
used as an indicator of [Ca*‘]i with values normalized to 0% in resting 
and 100% in high K’-stimulated muscle, respectively. 
2.3. Coniraction of skinned smooll~ rrruscle 
Skinned (permeabilized) smooth muscle was made by freezing the 
strips of guinea-pig taenia caeci or rabbit mesenteric artery (l-2 mg 
wet-weight) in liquid nitrogen followed by freeze-drying. Before use, 
the dried muscle strips were treated with a relaxing solution contain- 
2. MATERIALS AND METHODS 
ing 10% glycerol for 15 min. Other experimental procedures are 
similar to those described previously [7]. 
2.1. Protein phospkatases 
Type-l phosphatase was partially purified from turkey gizzard 
native actomyosin as described previously [S] with additional steps of 
ammonium sulfate fractionation between 30 and 60% saturation, 
followed by chromatography on Sephacryl S-300, DEAE-Sepharose 
Fast Flow and finally heparin-agarose, The catalytic subunit of type-l 
phosphatase from skeletal muscle was kindly provided by Drs D. 
Brautigan and 8. Martin (Brown University) and the catalytic subunit 
of type-2A phosphatase from bovine cardiac muscle by Dr M.C. 
Mumby (University of Texas). Phosphatase assays were carried out at 
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2.4. MLC phospkoryfation and MLC kinase 
Native actomyosirr was prepared from chicken gizzard [7]. MLC 
phosphorylation was determined by monitoring the shift in elec- 
trophoretic motility of MLC in a urea polyacrylamide gel [9]. Protein 
bands were visualized by means of the silver stain (71. MLC kinase 
was isolated from frozen turkey gizzard as described by Ikebe et al. 
1101. 
2.5. Drugs and chemicals 
The following drugs and chemicals were used: norepinephrine, 
vcrapamil (Sigma Chemical Co., St. Louis, hI0, USA) and acetoxy- 
methyl ester of fura- (Dojindo Lab., Kumamoto, Japan). 
Tautcmycin (donated by Dr Kiyoshi Isono, Riken: The Institute of 
Physical and Chemical Research), okadaic acid (donated by Dr 
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Table I 
Inhibition of protein phosphatascs by tautomycin, okadaic acid and 
calyculin-A 
Phosphatasc Tautomycin Okadaic acid Calyculin A 
lC50 (nM) 
Type-2A 32 10 3 
Type-l (smooth muscle) 32 224 5 
Type-l (skeletal muscle) 22 237 
Smooth muscle endogcnous 6 70 I 
- : not determined 
Daisukc Ucmura, Shizuoka University) and calyculin-A (donated by 
Dr Nobuhiro Fusetani, The University of Tokyo) were dissolved in 
1OOV’o ethanol to a IO mM stock. 
3. RESULTS 
As shown in Fig. 1 and Table I, tautomycin inhibited 
the type-l and type-2A phosphatases with 160 values 
of 22-32 nM and the smooth muscle endogenous 
phosphatase with an I&O of 6 nM. Okadaic acid and 
calyculin A are known inhibitors of these phosphatases 
l§,ll] and for comparison the effects of these com- 
pounds are included in Table I. Fautomycin, up to 
8OpM, did not influence the activity or calmodulin- 
dependence of MLC kinase (data not shown). 
As shown in Fig. 2, 10 pM tautomycin induced a sus- 
tained contraction of rat aorta with only a small in- 
crease in [Ca”‘]i. A Ca2+ channel blocker, 10 PM 
verapamil, decreased the tautomycin-induced increase 
in [Ca2+]i to resting levels. Subsequent addition of 
4 mM EGTA further decreased [Ca2’]i. However, 
neither verapamil nor EGTA inhibited the tautomycin- 
induced contraction. As shown in Fig. 3, cumulative 
Tautomycin (-IogM) 
Fig. 1. Inhibitory effect of tautomycin on protein phosphatases. 
Conditions see section 2. Catalytic subunits of type-l phosphatasc 
from smooth muscle (0) and skeletal muscle (0). Endogenous 
phosphatasc from smooth muscle (0). Catalytic subunit of type-2A 
phosphatasc (A). 
addition of tautomycin induced a graded sontraction in 
rat aorta with an lX50 of 2 FM. The contractile effect 
of tautomycin was not affected by removing external 
Cazc with EGTA. 
In rat aorta, high Kf (65.4 mM) or 1 yM 
norepinephrine induced sustained contraction. Addi- 
tion of tautomycin or calyculin-A during these contrac- 
tions induced additional increase in muscle tension 
(data not shown). By contrast, addition of okadaic acid 
inhibited the contraction at 0.1-l ,&I whereas higher 
concentrations of okadaic acid (2 10 @I) induced ad- 
ditional increase in muscle tension, as reported 
previously [ 121. 
Tautomycin induced contraction in the absence of 
Ca2+ (pea’+ c 1 nM) in skinned taenia and mesenteric 
artery (Fig. 3). The iC50 value of tautomycin for skinn- 
ed muscle fiber (14-17 nM) was approx. 100 times 
lower than those for intact smooth muscle. Similar 
observations were made previously with okadaic acid 
and calyculin A [7]. The reason for the different poten- 
cies of these compounds in skinned compared to intact 
fibers is due probably to limited diffusion across the 
plasma membrane or compartmentalization in the in- 
tact fiber. 
MLC was phosphorylated almost complstely in the 
presence of 100 PM Ca2+ and only 5% in the absence of 
Cat+, as reported previously [7]. In the absence of 
Ca”, 10 nM and 100 nM tautomycin increased the 
phosphorylation to 36% and 40070, respectively. 
Okadaic acid (100 nM) and calyculin-A (100 nM) also 
increased the phosphorylation to 32% and 42070, respec- 
tively, as reported previously [7]. 
4. DISCUSSION 
In the studies described above it was shown that 
tautomycin is an effective inhibitor of type-l and 
type-2A phosphatases. The 1Cs0 values for each 
phosphatase are similar and in this respect tautomycin 
resembles calyculin-A rather than okadaic acid since the 
latter is more effective with the type-2A enzyme [5]. 
Tautomycin appears to be slightly less potent than 
calyculin-A by a factor of about ten-fold, but this must 
be regarded as tentative until Ki values are determined. 
Phosphorylation of MLC by MLC kinase is accepted 
as a dominant mechanism in the regulation of contrac- 
tile activity in smooth muscle 113,141. Activation of 
MIX kinase occurs following an increase in [Ca’+]i and 
the formation of the ternary complex, Ca2+, 
calmodulin, MLC kinase. However, in these studies it 
was shown that tautomycin induces contraction of in- 
tact and skinned smooth muscle fibers in the absence of 
increased [Ca’+]i. The concentrations of tautomycin 
needed for contraction (1C50: 14-17 nM) and elevated 
phosphorylation (30 nM) in skinned fibers were similar 
to those concentrations required to inhibit protein 
phosphatase activities. In addition, there appears to be 
146 
Volume 285, number 1 Juiy i99i 
Fig. 2. Effect of tautomycin on [Cn’+]i and contractile tension in rat aorta. Muscle was first contracted in 72.7 mM KCI (made by replacing NaCl 
with KCI) and then with 1OpM tautomycin. Verapamil (IOpM) and 4 mM EGTA were sequentially added in the presence of tautomycin as 
indicated. 
no direct effect of tautomycin on MLC kinase activity. 
These results, therefore, support the hypothesis that the 
tautomycin-induced and Cazf-independent contraction 
is due to the ‘unmasking’ of significant MLC kinase ac- 
tivity via phosphatase inhibition. A similar conclusion 
was reached earlier for calyculin-A and okadaic acid 
[5,7]. It is surprising that the level of MLC kinase activi- 
I’ Skinned muscle Intact muscle II 
Tautomycin C-109 Ml 
Fig. 3. Concentration-response curves for contractile effect of 
tautomycin on intact rat aorta in the presence (+ Ca) or absence of 
Ca”+ ( - Ca), and on skinned smooth muscle of guinea-pig taenia and 
rabbit mesenteric artery. Values are mean & SEM of 4 muscle strips. 
100% for intact muscle (right ordinate) represents the contractile 
tension induced by 72.7 mM KCI and 100% for skinned muscle (left 
ordinate) represents the contractile tension induced by 100 nM 
taut7mycin. 
ty in resting cell is sufficient to account for this and the 
possibility that other kinases might be involved should 
be considered. In this regard it is interesting that the 
type II Ca’+/calmodulin-dependent protein kinase was 
recently shown to be capable of phosphorylating 
smooth muscle myosin [ 151. 
Okadaic acid has a dual effect on smooth muscle 
mechanics; at low concentrations it relaxes a contracted 
muscle strip and at higher concentrations it induces 
contraction 112,161. In the present experiment, it was 
found that neither tautomycin nor calyculin-A behaved 
similarly and neither inhibited contraction induced by 
high K+ or norepinephrine. Tentatively the distinctive 
behavior of okadaic acid may reflect its preferential in- 
hibition of type-2A phosphatase and the involvement of 
this enzyme in processes other than myosin 
phosphorylation. It follows therefore that the type-l 
phosphatase is more important in regulating 
phosphorylation of the myosin light chain. 
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